Advertisement
Compugen Ltd. (CGEN)
NASDAQ: CGEN
· Real-Time Price · USD
1.43
-0.01 (-0.69%)
At close: Apr 29, 2025, 11:25 AM
-0.69% (1D)
| Bid | 1.42 |
| Market Cap | 133.26M |
| Revenue (ttm) | 27.86M |
| Net Income (ttm) | -14.23M |
| EPS (ttm) | -0.16 |
| PE Ratio (ttm) | -8.91 |
| Forward PE | -7.76 |
| Analyst | Buy |
| Ask | 1.43 |
| Volume | 64,568 |
| Avg. Volume (20D) | 382,570 |
| Open | 1.45 |
| Previous Close | 1.44 |
| Day's Range | 1.42 - 1.45 |
| 52-Week Range | 1.13 - 2.66 |
| Beta | 3.20 |
About CGEN
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients wi...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 11, 2000
Employees 74
Stock Exchange NASDAQ
Ticker Symbol CGEN
Website https://cgen.com
Advertisement
Analyst Forecast
According to 1 analyst ratings, the average rating for CGEN stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 180.70% from the latest price.
Stock ForecastsNext Earnings Release
Compugen Ltd. is scheduled to release its earnings on May 19, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
